[Frontiers In Bioscience, Landmark, 23, 2082-2089, June1, 2018]

Role of alpha1-adrenergic receptor antibodies in Alzheimer’s disease

Peter Karczewski1, Petra Hempel1, Marion Bimmler1

1E.R.D.E.-AAK-Diagnostik GmbH, Berlin, Germany

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. G-protein-coupled receptor (GPCR) autoantibodies in dementia
4. Receptor activation by agonistic autoantibodies in patients with Alzheimer’s disease
5. Animal models
6. Clinical findings
7. Conclusions
8. Acknowledgements
9. References

1. ABSTRACT

Agonistic autoantibodies (agAAB) for alpha-1 adrenoceptor were found in approx. 50% of patients with Alzheimer’s disease. These antibodies activate the receptor and trigger the signal cascades similarly to how natural agonists do. The agAAB bond to the receptor is persistent and prolonged. This results in a non-physiological elevation of intracellular calcium. An animal model has shown that agAAB causes macrovascular and microvascular impairment in the vessels of the brain. Reduction in blood flow and the density of intact vessels was significantly demonstrated. The agAAB was removed through immunoadsorption in a small cohort of patients with Alzheimer’s disease. Subsequent follow-up observations over 12-18 months noted stabilization of cognition levels.

9. REFERENCES

1. H Bickel: Die Epidemiologie der Demenz. Deutsche Alzheimer-Gesellschaft 2012, Berlin, Germany.

2. JC De la Torre: Alzheimer disease as a vascular disorder: nosological evidence. Stroke 33, 1152–1162 (2002)
DOI: 10.1161/01.STR.0000014421.15948.67

3. Y Ni, X Zhao, G Bao, L Zou, L Teng, Z Wang, M Song, J Xiong, Y Bai, G Pei: Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat Med 12, 1390–1396 (2006)
DOI: 10.1038/nm1485

4. W Xu, C Qiu, M Gatz, NL Pedersen, B Johansson, L Fratiglioni: Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 58, 71–77 (2009)
DOI: 10.2337/db08-0586

5. MM Breteler: Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiol Aging 21, 153–160 (2000)
DOI: 10.1016/S0197-4580(99)00110-4

6. H Umegaki: Type 2 diabetes as a risk for cognitive impairment: current insights. Clin Interv Aging 9, 1011–1019 (2014)
DOI: 10.2147/CIA.S48926

7. DW Desmond, JT Moroney, M Sano, Y Stern: Incidence of dementia after ischemic stroke. Results of a longitudinal study. Stroke 33, 2254–2262 (2002)
DOI: 10.1161/01.STR.0000028235.91778.95

8. P Hein, MC Michel: Signal transduction and Regulation: Are all α1-adrenergic receptor subtypes created equal? Biochem Pharmacol 73, 1097–1106 (2007)
DOI: 10.1016/j.bcp.2006.11.001

9. P Karczewski, P Hempel, R. Kunze M. Bimmler: Agonistic Autoantibodies to the α1-Adrenergic Receptor and the β2-Adrenergic Receptor in Alzheimer’s and Vascular Dementia. Scand J Immunol 75, 524–530 (2012)
DOI: 10.1111/j.1365-3083.2012.02684.x

10. A Mijares, D Lebesgue, G Wallukat, J Hoebeke: From agonist to antagonist: Fab fragments of an agonist-like monoclonal anti-β2-adrenoceptor antibody behave as antagonists. Mol Pharmacol 58, 373-379 (2000)
DOI: 10.1124/mol.58.2.373

11. B Bornholz, S Weidtkamp-Peters, S Schmitmeier, CAM Seidel, LR Herda, SB Felix, H Lemoine, J Hescheler, F Nguemo, C Schäfer, MO Christensen, C Mielke, F Boege: Impact of human autoantibodies on ß1-adrenergic receptor conformation, activity, and internalization. Cardiovasc Res 97, 472–480 (2013)
DOI: 10.1093/cvr/cvs350

12. P Karczewski, H Haase, P Hempel, M Bimmler: Agonistic antibody to the α1-adrenergic receptor mobilizes intracellular calcium and induces phosphorylation of a cardiac 15-kDa protein. Mol Cell Biochem 333, 233–242 (2010)
DOI: 10.1007/s11010-009-0224-0

13. K Wenzel, H Haase, G Wallukat, W Derer, S Bartel, V Homuth, F Herse, N Hubner, H Schulz, M Janczikowski, C Lindschau, C Schroeder, S Verlohren, I Morano, DN Müller, FC Luft, R Dietz, R Dechend, P Karczewski: Potential Relevance of a1-Adrenergic Receptor autoantibodies in refractory hypertension. PLoS One 3, e3742 (2008)
DOI: 10.1371/journal.pone.0003742

14. P Karczewski, H Haase, P Hempel, M Bimmler: Antibodies against the α1-adrenergic receptor mobilize intracellular calcium and induce the phosphorylation of phospholemman. Clin Res Cardiol Suppl 1, P1331 (2010)

15. R Jahns, V Boivin, L Hein, S Triebel, CE Angermann, G Ertl, MJ Lohse: Direct evidence for a β1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 113, 1419–1429 (2004)
DOI: 10.1172/JCI200420149

16. CC Zhou, Y Zhang, RA Irani, H Zhang, T Mi, EJ Popek, MJ Hicks, SM Ramin: Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 14, 855–862 (2008)
DOI: 10.1038/nm.1856

17. D Dragun, DN Müller, JH Bräsen, L Fritsche, M Nieminen-Kelhä, R Dechend, U Kintscher, B Rudolph, J Hoebeke, D Eckert, I Mazak, R Plehm, C Schönemann, T Unger, K Budde, HH Neumayer, FC Luft, G Wallukat. Angiotensin II type 1-receptor activating antibodies in renal allograft rejection. N Engl J Med 352, 558–569 (2005)
DOI: 10.1056/NEJMoa035717

18. Z Zhou, Y Liao, L Li, F Wei, B Wang, Y Wei, M Wang, X Cheng: Vascular damages in rats immunized by alpha1-adrenoceptor peptides. Cell Mol Immunol 5, 349–356 (2008)
DOI: 10.1038/cmi.2008.43

19. P Karczewski, A Pohlmann, B Wagenhaus, N Wisbrun, P Hempel, B Lemke, R Kunze, T Niendorf, M Bimmler: Antibodies to the alpha1-adrenergic receptor cause vascular impairments in rat brain as demonstrated by magnetic resonance angiography. PLoS One 7, e41602 (2012)
DOI: 10.1371/journal.pone.0041602

20. A Pohlmann, P Karczewski, CM Ku, B Dieringer, H Waiczies, N Wisbrund, S Kox, I Palatnik, HM Reimann, C Eichhorn, S Waiczies, P Hempel, B Lemke, T Niendorf, M Bimmler: Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4. T reveals microvascular impact of α1-adrenergic receptor antibodies. NMR Biomed 27, 1085–1093 (2014)
DOI: 10.1002/nbm.3160

21. AO Doesch, S Mueller, M Konstandin, S Celik, A Kristen: Effects of protein A immunoadsorption in patients with chronic dilated cardiomyopathy. J Clin Apher 25, 315-322 (2010)
DOI: 10.1002/jca.20263

22. M Dandel: Immunoadsorption Therapy in Heart Transplant Candidates with Idiopathic Dilated Cardiomyopathy and Evidence of Beta-1 Adrenoceptor Autoantibodies. Clin Res Cardiol 99, Suppl 1 (2010)

23. PF Klein-Weigel, M Bimmler, P Hempel, S Schöpp, S Dreusicke, J Valerius, A Bohlen, JM Boehnlein, D Bestler, S Funk, S Elitok: G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger’s disease) and their removal by immunoadsorption. Vasa 43, 347–352 (2014)
DOI: 10.1024/0301-1526/a000372

24. P Hempel, B Heinig, C Jerosch, I Decius, P Karczewski, U Kassner, R Kunze, E Steinhagen-Thiessen, M Bimmler: Immunoadsorption of Agonistic Autoantibodies Against α1-Adrenergic Receptors in Patients with Mild to Moderate Dementia. Ther Apher Dial 20(5), 523-529 (2016)
DOI: 10.1111/1744-9987.12415

25. C Courtney, D Farrell, R Gray, R Hills, L Lynch, E Sellwood, S Edwards, W Hardyman, J Raftery, P Crome, Lendon, H Shaw, P Bentham: Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363(9427), 2105-2115 (2004)
DOI: 10.1016/S0140-6736(04)16499-4

26. RS Doody, RG Thomas, M Farlow, T Iwatsubo, B Vellas, S Joffe, K Kieburtz, R Raman, X Sun, PS Aisen, E Siemers, H Liu-Seifert, R Mohs: Alzheimer’s Disease Cooperative Study Steering Committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370, 311–321 (2014)
DOI: 10.1056/NEJMoa1312889

27. S Salloway, R Sperling, NC Fox, K Blennow, W Klunk, M Raskind, M Sabbagh, LS Honig, AP Porsteinsson, S Ferris, M Reichert, N Ketter, B Nejadnik, V Guenzler, M Miloslavsky, D Wang, Y Lu, J Lull, IC Tudor, E Liu, M Grundman, E Yuen, R Black, HR Brashear, Bapineuzumab 301 and 302 Clinical Trial Investigators: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 370, 322-333 (2014)
DOI: 10.1056/NEJMoa1304839

28. LA Demetrius, PJ Magistretti, L Pellerin: Alzheimer’s disease: the amyloid hypothesis and the Inverse Warburg effect. Front Physiol 5, 522 (2014)
DOI: 10.3.389/fphys.2014.0.0522

29. Patent: EP 2742065, USA 9,708,372. Titel: Agonistic autoantibodies to the a1-adrenergic receptor and the ß2-adrenergic receptor in Alzheimer´s and vascular dementia

Key Words: Dementia, Agonistic Autoantibodies, Immunoadsorption, Review

Send correspondence to: Marion Bimmler, E.R.D.E.-AAK-Diagnostik GmbH, Berlin, Germany, Tel: 00493094892227, Fax:00493094892229, E-mail: bimmler@mdc-berlin.de